MedImmune Reports Preliminary Vitaxin Data
MedImmune (MEDI) said the preliminary data from a study involving patients with stage IV metastatic melanoma showed a 12.7-month median survival for those treated with Vitaxin alone.
Data also showed a 9.4-month median survival for patients treated with Vitaxin plus dacarbazine (DTIC). In a separate recent Phase III trial, patients treated with DTIC alone, the current standard of care in advanced melanoma, had a median survival of 7.9 months, the company said.
Vitaxin is MedImmune's development-stage monoclonal antibody being evaluated in separate trials involving patients with advanced melanoma and prostate cancers. The data from the melanoma trial were presented at the American Society of Clinical Oncology annual meeting.
The preliminary data demonstrated that the one-year survival rate was 53% for patients receiving Vitaxin alone, while the one-year survival rate was 42% for patients receiving Vitaxin plus DTIC. Data on three patients are still pending.In the study, 112 patients with stage IV metastatic melanoma received weekly intravenous infusions of Vitaxin either alone or in conjunction with DTIC once every three weeks. To date, safety data suggest that Vitaxin has been generally well tolerated in these patients. Immunogenecity data are pending.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV